As Director of Global Oncology Policy for Endpoints and Pricing & Reimbursement (P&R) reform, you will play a pivotal role in channeling our capabilities to promote the acceptability and appropriate valuation of oncology endpoints. Additionally, supporting access to new treatments for the benefit of cancer patients, healthcare systems, and AstraZeneca.
You'll advise on AstraZeneca’s global policy strategy, guide internal and external resources
and engage externally to help health systems and AstraZeneca succeed in:
Together with external partners you'll communicate evidence and argumentation about the appropriateness and value of non-OS endpoints and Patient Reported Outcomes (PROs) in specific tumor types and lines of therapy relevant to AstraZeneca. Areas of focus include early stage lung cancer and ovarian cancer amongst others.
We need you to inspire change in stakeholder attitudes and country policies towards the use of non-OS endpoints and PROs for the initial P&R of AstraZeneca medicines. Success will be identified by the strength and quality of international consensus and of stakeholder advocacy at country and above-country levels.
We will encourage you to share innovative ideas how to address the challenge of overall survival (OS) in payer and HTA agency evaluations, and come equipped with an infectious energy, an entrepreneurial attitude and proven track record to move mountains through collaboration.